We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+7.08%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.36B
AUM Growth
-$71M
Cap. Flow
-$199M
Cap. Flow %
-8.42%
Top 10 Hldgs %
44.44%
Holding
74
New
10
Increased
32
Reduced
22
Closed
10

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$49.8M
2
XLRN
Acceleron Pharma
XLRN
+$19.7M
3
RLYP
RELYPSA INC COM
RLYP
+$16.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
5
PTCT icon
PTC Therapeutics
PTCT
+$12.9M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$55.6M
2
AGN
Allergan Inc
AGN
+$47.4M
3
GILD icon
Gilead Sciences
GILD
+$43.5M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$43.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
51
Cigna
CI
$75.1B
$7.8M 0.33%
+84,832
New +$7.28M
NXTM
52
DELISTED
NxStage Medical Inc.
NXTM
$7.12M 0.3%
495,556
-909
-0.2% -$11.9K
INGN icon
53
Inogen
INGN
$173M
$6.34M 0.27%
281,200
-2,210
-0.8% -$36.6K
NVO
54
Novo Nordisk
NVO
$219B
$5.98M 0.25%
259,020
-14,200
-5% -$314K
IRWD icon
55
Ironwood Pharmaceuticals
IRWD
$634M
$5.53M 0.23%
430,704
-5,112,061
-92% -$55.6M
TBPH icon
56
Theravance Biopharma
TBPH
$871M
$4.85M 0.21%
+152,151
New +$4.58M
ARAY icon
57
Accuray
ARAY
$29.8M
$4.33M 0.18%
491,505
+7,766
+2% +$67.3K
NVS icon
58
Novartis
NVS
$285B
$3.14M 0.13%
38,725
+3,906
+11% +$307K
RNA
59
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$957K 0.04%
+75,834
New +$615K
TNDM icon
60
Tandem Diabetes Care
TNDM
$1.24B
$898K 0.04%
5,523
+2,513
+83% +$428K
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$813K 0.03%
+40,525
New +$571K
MDVN
62
DELISTED
MEDIVATION, INC.
MDVN
$789K 0.03%
+20,466
New +$690K
ANTH
63
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$744K 0.03%
27,451
-232
-0.8% -$5.73K
WX
64
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$434K 0.02%
13,193
+6,503
+97% +$223K
ABUS icon
65
Arbutus Biopharma
ABUS
$871M
– –
-27,500
Closed -$591K
CARM
66
DELISTED
Carisma Therapeutics
CARM
– –
-2,500
Closed -$812K
CLDX icon
67
Celldex Therapeutics
CLDX
$2.78B
– –
-93,927
Closed -$24.9M
CBIO
68
Crescent Biopharma
CBIO
$537M
– –
-446
Closed -$728K
IONS icon
69
Ionis Pharmaceuticals
IONS
$8.75B
– –
-882,101
Closed -$38.1M
NGNE icon
70
Neurogene
NGNE
$745M
– –
-1,500
Closed -$382K
APEN
71
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-1,642
Closed -$601K
FPRX
72
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-32,372
Closed -$636K
AEGR
73
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-934,100
Closed -$43.1M
FRX
74
DELISTED
FOREST LABORATORIES INC
FRX
– –
-270,100
Closed -$24.9M
1 2
3

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sectoral Asset Management held 74 positions worth $2.36B, down 2.9% from $2.43B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sectoral Asset Management withdrew a net $199M in Q2 2014, closing 10 positions and reducing 22 holdings. Its most notable exit was Aegerion Pharmaceuticals, an estimated $43.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Perrigo worth $51.2M.

  • Sectoral Asset Management's largest Q2 2014 buy was Perrigo: 351,368 shares worth $51.2M.
  • Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q2 2014, an estimated $14.6M increase.
  • Sectoral Asset Management's biggest Q2 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $55.6M.
  • Sectoral Asset Management fully exited Aegerion Pharmaceuticals in Q2 2014, selling an estimated $43.1M.
  • Sectoral Asset Management's ten largest holdings make up 44% of its $2.36B portfolio in Q2 2014.
  • Sectoral Asset Management opened 10 new positions and closed 10 in Q2 2014.
  • Sectoral Asset Management's portfolio value fell 2.9% quarter-over-quarter to $2.36B.

Based on Sectoral Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.